Rol de los inflamasomas en pacientes con hipertensión resistenteen los pacientes derivados de hospitales de la Provincia de Mendoza
Ischemic heart disease (CHD) remains one of the main causes of global mortality despite the evidence-based therapies obtained from clinical trials. Although significant resources are allocated to develop newer treatments, resistant hypertension (HTR) and lack of adherence to medications prevent achi...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Publicado: |
2019
|
| Materias: | |
| Acceso en línea: | https://bdigital.uncu.edu.ar/fichas.php?idobjeto=14752 |
| Sumario: | Ischemic heart disease (CHD) remains one of the main causes of global mortality despite the evidence-based therapies obtained from clinical trials. Although significant resources are allocated to develop newer treatments, resistant hypertension (HTR) and lack of adherence to medications prevent achieving adequate goals. In acute, primary and secondary medical care environments, lack of adherence undermines evidence-based therapy, allowing the number of patients with hypertension to be increased even if medicated (real resistance), contributing to hundreds of thousands of deaths per year and unnecessary expenses. Medical care exceeding hundreds of billions of dollars in the United States and European countries.Identifying underlying mechanisms to identify high-risk patients is a useful tool to reduce the incidence of severe cardiovascular events. Hypertension is the most frequent pathology worldwide, and of course even more in developing countries. In Mendoza the prevalence exceeds 33%. The HTR is the most serious affectation within the AHT, having the highest prevalence of stroke, heart disease, ischemia and death. It is defined with the persistence of figures tensions higher than 140/90 despite having treatment of 3 different pharmacological groups. Inflammasomes are fundamental components of inflammation, mainly the inflammable NLRP3, composed of CASP-1 and IL-1B.The working hypothesis suggests that these components mediate pharmacological resistance and that its detection can contribute to identify and adequately treat the patient as well as open the field to future specific pharmacological treatment. |
|---|
